acid isoforms were made by deacylation of renal Gb 3 and reacylation of lyso-Gb 3 with a single fatty acid as previously described ( 9 ) .
Labeling of verotoxin

125
I VT1 and 125 I VT2 were prepared using Iodogen (Pierce) under conditions previously described ( 26 ) , which have no effect on Gb 3 binding or cell cytotoxicity.
Gb 3 /cholesterol DRM construction
Gb 3 /cholesterol DRM were generated as described ( 23 ) . Briefl y, a 2:1 ratio of Gb 3 (50 µg) and cholesterol (25 µg) in ethanol were dried together and dissolved in 750 µl of MES-Triton buffer (25 mM MES, 150 mM NaCl pH 7.2, 1% Triton X-100). The solution was vortexed (1 min), sonicated (1 min), heated at 55°C (5 min) and vortexed (1 min). Then 750 µl of 70% sucrose solution in MES (pH 7.2) was added, gently mixed, and allowed to stand at room temperature for about 1 h. The mixture was then placed below 1 ml of 30% sucrose containing 1 µg.ml -1 125 I-VT1. This was then overlaid successively with 1 ml of 30% sucrose and 1.5 ml of 5% of sucrose and condensed lipid species separated by fl oatation ultracentrifugation at 14,000 g for 72 h at 20°C. Although cell DRM are often isolated at 4°C, we found that separation was not altered at room temperature. From the top of the tube, 10 fractions, 500 µl each, were collected and counted in a ␥ Ϫ counter.
Immunoblot analysis of DRM fractions
Aliquots of the gradient fractions were loaded on to nitrocellose using a Slotblot apparatus (Shliecher and Schuell Minifold I microsample fi ltration manifold). The samples were washed with 50 mM TBS, 150 mM NaCl containing 1% skim milk blocking solution and left at 37°C for 1 h. The membrane was rinsed with TBS and incubated with anti gp120-Mab F425 B4a1 or Mab anti VT1 (1µg/ml), as appropriate, for 2 h at room temp. After washing, bound antibody was detected using an appropriate HRP conjugated anti-species antibody.
Langmuir trough monolayer surface pressure
The surface pressure was measured with a fully automated microtensiometer (µTROUGH S, Kibron Inc., Helsinki, Finland). The apparatus allowed the recording of the kinetics of interaction of a ligand with the monomolecular fi lm using a set of specially designed Tefl on troughs. All experiments were carried out in a controlled atmosphere at 23°C ± 0.5°C. Monomolecular fi lms of Gb 3 or Gb 3 analogs (1-2µg) ± cholesterol were spread on pure water subphases (400 µl) from hexane/chloroform/ethanol solution as described previously ( 24, 27 ) . After spreading the fi lm, 5 min was allowed for solvent evaporation. To measure the interaction of VT1, VT2 or gp120 with Gb 3 monolayers, the ligand was injected in the subphase with 10 µl Hamilton syringe, and pressure increases produced were recorded for the indicated time. The data were analyzed with the Filmware version 3.57 program (Kibron Inc., Finland). The accuracy of the system under our experimental conditions was ± 0.25 mN.m Ϫ 1 for surface pressure. 
RESULTS
Gb 3 fatty acid chain content effects
VT1 binding to Gb 3 /cholesterol DRM constructs. Human renal Gb 3 comprises C16 (21%), C18 (5%), C20 (9%), C22 (15%), C24 (27%), and C24:1 (23%) fatty acids ( Fig. 1i ) . Accordingly, these isoforms were synthesized from lysoGb 3 and assessed for model DRM VT binding.
The 125 I-VT1/Gb 3 DRM gradient profi les (Fig. 1ii) show VT1 was bound only in fraction 1 (± fraction 2). Gb 3 /cholesterol DRMs containing C16 fatty acid showed 75% binding compared with renal Gb 3 . Surprisingly, no VT1 binding to either C18 or C20 fatty acid Gb 3 DRM (6.6% and 3%, respectively) was observed ( Table 1 ) . No VT1 bound to the nonphysiological C17Gb 3 either. Longer chain fatty acid Gb 3 DRMs (C22 and C24) showed about 75% and 50% binding, respectively. ␣ -Hydroxylation of C18Gb 3 had no effect on VT1 binding. In contrast, ␣ -hydroxylation of C22Gb 3 dramatically decreased the binding to Gb 3 DRMs [ Fig. 1ii Table 1 ]. In all cases, no binding to the gradient fraction containing most Gb 3 (fraction 5) [ Fig. 1ii (A)(ii)] was seen, and this has been studied separately (Mahfoud, R., A. Manis, C. Ackerley, and C. Lingwood, unpublished observations). The nature of the fatty acid only affected binding to the Gb 3 DRMs at the gradient top (fraction 1 ± 2).
VT1-DRM binding to mixed Gb 3 DRMs
VT1 binding to in vitro reconstituted Gb 3 was initially addressed by mixing the different Gb 3 fatty acid isoforms [C16 (27%) + C18 (11%) + C20 (11%) + C22 (18%) + C24 (33%)] according to the composition of renal Gb 3 ( Fig.  1i ) . Due to the tendency of unsaturated fatty acid containing GSL to be excluded from DRM ( 28-31 ), C24:1Gb 3 was not initially included. Fig. 2A compares the binding profi le of 125 I-VT1 to renal Gb 3 (considered as control) to a corresponding Gb 3 mixture. Surprisingly, there was no signifi cant VT1/DRM binding. Then we removed the individually VT1 unbound Gb 3 species. VT1 binding was signifi cantly augmented upon removal of the C18 isoform (200% control; Fig 2B) . Removal of C20 had a lesser, but signifi cant, effect (100% control; Fig. 2B ). Addition of ␣ -hydroxylated C18 increased VT1 binding and addition of ␣ -hydroxylated C22 showed 100% control binding ( Fig. 2C ) .
Counter to the perceived incompatibility of unsaturation with "raft" formation, when we added the missing 3 to the mixture [C16 (21%) + C18 (5%) + C20 (9%) + C22 (15%) + C24 (27%) + C24:1 (23%)], a significant increase in binding was seen (100% control; Fig. 2D) . The 125 I-VT1 profi le of the mixture could now be superimposed on that of native renal Gb 3 . In binary Gb 3 DRM constructs, C24:1 increased VT1 binding and countered C18 and C20Gb 3 ( Table 2 ).
These studies indicate that the individual Gb 3 fatty acid isoforms form a balance within these fraction 1 Gb 3 /cholesterol-DRM to promote or prevent VT1 recognition. However, for fraction 5 DRM, Gb 3 is not recognized, irrespective of fatty acid content.
Modulation of VT1 recognition of Gb 3 fatty acid isoform DRMs
For fatty acid species not bound by VT1, the Gb 3 distribution was not different from VT1-bound Gb 3 fatty acid isoforms ( Fig. 3 ) . The inhibitory effect seen with C18 and 
VT2 Gb 3 DRM binding is largely independent of fatty acid content
As shown in Table 1 , fatty acid chain length did not affect VT2 binding to fraction 1 Gb 3 /cholesterol DRM, as seen for VT1. VT2 more effi ciently bound Gb 3 C22, and C16 DRM (227% and 118% renal control, respectively), but all fatty acid isoforms were bound by VT2. The saturated isoform mixture not bound by VT1 was bound by VT2, and addition of Gb 3 C24:1 to this in vitro reconstituted Gb 3 mixture did not affect VT2 binding. Nevertheless, no VT2 binding to fraction 5 DRM was observed.
HIV gp120 binding to Gb 3 fatty acid isoform DRMs mimics that of VT1
Gp120 binding within fraction 1 of single fatty acid isoform Gb 3 /cholesterol DRMs was similar to VT1 ( Fig. 4 ). There was effi cient binding to C16Gb 3 DRMs, poor or no binding to C18 or C20Gb 3 DRMs, strong binding to C22Gb 3 DRMs, and reduced recognition of C24Gb 3 DRMs. In each case, no binding within fraction 5 DRM was seen.
HIV gp120 binding to mixed Gb 3 fatty acid isoform DRM mimics that of VT1
As for VT1, mixing the individual Gb 3 fatty acid isoforms to reconstitute the renal Gb 3 composition results in gp120 binding vesicles in fraction 1 ( Fig. 5B ) . As for VT1, omission of the C24:1Gb 3 results in the complete loss of binding ( Fig. 5C ). Removal of C18 or C20 from the C24:1 defi cient mix had no effect ( Figs. 5D and 5E ), but removal of both induced gp120 binding ( Fig. 5F ). Mixing C18 and C24:1 fatty acid Gb 3 s, which alone show no binding, generates gp120 binding DRMs ( Fig. 5G ).
Monolayer surface pressure shows unique profi le for VT1 C18 and C20Gb 3 A Langmuir fi lm balance was used to examine ligand binding to Gb 3 ± cholesterol. VT1 binding/insertion to renal Gb 3 monolayers showed a sigmoidal increase in surface pressure, enhanced in the presence of cholesterol [ Fig. 6i (A) and Table 3 ]. The interaction was dose dependent (not shown) with a maximal surface pressure increase at 200 nM. Specifi city of the VT-Gb 3 interaction was assessed by increasing the initial surface pressure ( i) to reduce the maximum surface pressure increase( ⌬ max). At a i р 30 mN/m, corresponding to a fl uid disordered (l d ) phase, the ⌬ max induced by VT1 was about 6 mN/m [ Fig. 6i(A) and Table 2] . For values of i greater than 30 mN/m, which correspond to raft-like liquid-ordered (l o ) phase domains ( 31 ), ⌬ max gradually decreased as i increased. This demonstrates the high specifi city of the interaction as previously established for several other lipids and ligands ( 18, 34 ) . The critical pressure of insertion (i.e., the theoretical value of i extrapolated for ⌬ max = 0 mN/m) was 42 mN/m. Interestingly, the mean lipid density of cellular membranes corresponds to a surface pressure of at least 30 mN/m ( 34 ) .Thus, these data suggest that the interaction of VT1 with Gb 3 requires a densely packed organization of GSL, likely to occur within lipid rafts. However, VT2 could interact with renal Gb 3 only when the fi lm was prepared at a low i (less than 30 mN/m) ( Fig. [6i( B) ]. No interaction occurred at the physiological pressure of 30 mN/m and cholesterol had signifi cantly less effect ( Fig. 6i( B) ] than for VT1. VT1 effi ciently bound C16 and C22Gb 3 [ Fig. 6 ii(A), Fig.  6ii(D) , and Table 3 ]. However, for C18 and C20Gb 3 no specifi c binding was apparent [ Figs. 6 ii(B) and 6ii(C)]. The ⌬ max was unaltered by increasing i. However, with cholesterol, VT1 binding/insertion to C18 or C20Gb 3 was restored ( Fig. 6 and Table 3 ). Thus, cholesterol fl uidizes the C18/C20Gb 3 monolayer to allow VT1 insertion. In contrast, VT2 was found to bind both C16 and C18Gb 3 effi ciently [ Figs. 6 ii(E) and 6ii(F)]. For these isoforms, especially C18Gb 3 , VT2 is able to bind at high initial surface pressure ( i greater than 30 mN/m). Similarly VT2c, which is much less cytotoxic than VT1 or VT2 ( 26 ) Fig. 6iii(D) ]. The VT1/gp120 selective transition between C16 and C18Gb 3 corresponds to the loss of VT1 and gp120 (but not VT2) binding within the sucrose gradient Gb 3 DRM constructs. In this case, addition of the unsaturated C24:1Gb 3 , also increasing fl uidity, induced VT1 binding. Thus the lack of binding to C18 and C20Gb 3 may be due to excessive rigidity (order) the lateral interaction of these isoforms may achieve.
DISCUSSION
Resistance to cold detergent extraction is a common approach to the study of cellular lipid rafts ( 35 ) that are enriched in cholesterol and GSLs ( 36 ) . Although DRMs represent a useful index of cell membrane architecture ( 37 ), the procedure does not result in membranes which refl ect the original membrane organization ( 35 ) , but rather an amalgam of originally potentially distinct domains. The GSL/cholesterol ratio (about 1.4) of our DRM vesicles represents a transition for micelle and vesicle formation ( 38 ) and is thus the simplest DRM system to study aglycone modulation of GSL receptors. These vesicles do not refl ect the more complex lipid composition of cell DRMs, but they provide a manipulable analytical tool. To improve resolution, we centrifuged for longer than is typical for cell-derived DRMs and separated two vesicle populations, one at the gradient top which binds ligand and a second fraction of larger vesicles that remain ligand unbound (Mahfoud, R., A. Manis, C. Ackerley, and C. Lingwood, unpublished observations).
Our studies show two precise transitions in the Gb 3 fatty acid alkyl chain length which regulate carbohydrate presentation for ligand binding in this model DRM vesicle system. No VT1 or gp120 binding is seen between C17 and C20, either in the cholesterol vesicle constructs separated saturation. Using a cholesterol/PC/Gb 3 ELISA, increasing fatty acid chain length (from C16 to C24) and unsaturation promoted VT1 binding ( 9 ) and differentially affected the binding of VT1 and VT2c in solid phase assays ( 9, 11 ) . Our evidence has indicated that such changes are also important in VT1/VT2 binding to Gb 3 within the human renal glomerulus ( 14 ) . The lipid moiety itself is crucial to the verotoxin receptor function of Gb 3 as the lipid-free sugar shows little VT binding (42) (43) (44) . In addition to VT binding, intracellular routing of the toxin Gb 3 complex within cells correlates with the lipid moiety ( 15 ) . After multivalent binding to Gb 3 receptors, VT1 (and VT2) ( 7 ) is internalized via receptor-mediated endocytosis by both clathrin ( 45, 46 ) and caveolar ( 47-49 ) mediated mechanisms. Then the toxin follows a retrograde transport route to the Golgi apparatus and endoplasmic reticulum (ER) ( 15, 46, (50) (51) (52) where the A subunit is translocated to the cytosol to inhibit protein synthesis ( 7 ) . Despite equivalent Gb 3 expression, cells with higher levels of shorter fatty acid (C16:0,C18) containing Gb 3 were signifi cantly more sensitive to VT1 compared with a cell line with higher levels of longer fatty acid (C24:0) Gb 3 content ( 53 ). VT1 was directed only to the Golgi region in less sensitive cells while within the same time frame, retrograde transport of VT1 to ER and nuclear membrane took place in highly sensitive cells ( 15, 53 ) . We proposed that Gb 3 isoforms with long chain fatty acids preferentially remain in the plasma membrane, whereas short chain fatty acid Gb 3 isoforms are preferentially internalized to mediate retrograde transport and VT1 cytotoxicity. VT1 B subunit within this pathway remains within the DRM fraction in sensitive cells but is found within the non-DRM fraction in Gb 3 positive, VT resistant cells in which internalized toxin is traffi cked to the lysosome ( 3, 54 ). However, although DRM and non-DRM Gb 3 may be differentially traffi cked within the cell, this does not provide the basis for retrograde transport. Gb 3 DRM binding is essential for VT cytotoxicity via ER cytosolic translocation ( 4 ) . Surprisingly, dissociation from DRMs did not affect VT1 retrograde transport to the Golgi/ER ( 4 ). VT1 internalization alters the subsequent plasma membrane Gb 3 content during a long lasting recovery phase ( 55 ), suggesting that a particular Gb 3 assembly is internalized by VT and traffi cked to the ER. VT1 and VT2 bind both shared and distinct cell surface domains which remain distinct/ common during internalization and retrograde transport. Unlike VT1, much of VT2 binds and is internalized with transferrin but intracellular VT1 and VT2 transport coalesce at the Golgi ( 7 ). Cell bound VT1 is more detergent resistant than VT2 and binding to cell derived or in vitro constructed Gb 3 DRMs is more signifi cant for VT1 ( 7 ) . This correlates with our current monolayer studies which show VT1, but not VT2, is able to bind and insert in to Gb 3 monolayers at surface pressures corresponding to liquid ordered domains. Increased cholesterol inhibited VT1 (but not VT2) Gb 3 DRM binding and sphingomyelin preferentially augmented VT2 Gb 3 DRM binding ( 7 ) . Thus these toxin homologs bind different Gb 3 lipid assemblies.
Though the affi nity for Gb 3 binding by VT2 is less than that of VT1, it is clear from renal tissue ( 14 ) and fraction 1 Gb 3 DRM binding, that VT2 is less restrictive as to the lipid on a sucrose gradient or in water/air interface monolayers. This is not an exclusion of Gb 3 carbohydrate for ligand binding, for in each case, VT2 binding is largely unaffected. By TLC overlay, each of the Gb 3 isoforms is effectively bound by both VT1 and VT2.
This C16/C17 Gb 3 alkyl chain transition is similar to that reported for saturated phospholipid/cholesterol bilayer interaction ( 39 ) . Cholesterol matches the dimensions of C16 alkyl chain to reduce PC alkyl chain tilt, whereas the overlap of C18 deformed the PC/cholesterol bilayer structure. Cholesterol stabilizes the gel phase to increase the transition temperature for PC alkyl chain length <C17 but destabilizes to decrease transition temperature for fatty acids >C18 ( 40 ) , although species longer than C20 were not assessed. This transition approximates to the 20Å long axis of cholesterol. However both alkyl chains were homologous, whereas in our studies the sphingosine remains constant. Our fi nding essentially the same transition, indicates cholesterol-fatty acid mismatch provides the basis of Gb 3 fatty acid dependent receptor function. Phospholipid fatty acid unsaturation decreases interaction with cholesterol ( 41 ) consistent with the dominant positive effect of C24:1Gb 3 we observed.
As for other GSLs, the lipid moiety of Gb 3 is heterogeneous in fatty acid chain length, ␣ -hydroxylation, and un- context in which Gb 3 is recognized. That this VT1 restriction is shared by HIV gp120, suggests that this is a significant, rather than subtle, conformational difference. Gb 3 has been implicated both as a cofactor for gp120 ( 56 ) and as a resistance factor against HIV ( 21, 22 ) and gp120-GSL binding is modulated by the lipid moiety ( 57 ) .
In the present experiments, we studied the effect of the Gb 3 fatty acid chain length, ␣ -hydroxylation and unsaturation on the binding of VT to Gb 3 DRMs. Early studies showed that C16, C18, C22, C24 and C24:1 fatty acids were the most common species in all the GSL fractions of human kidney ( 58 ) . Our analysis of the human kidney showed similar results ( 10, 14 ) . Hydroxylated fatty acids were only a minor component ( 10, 14 ) . The basis of cellular GSL fatty acid heterogeneity lies at the level of ceramide synthase, since several fatty acid selective ceramide synthase isoforms have been defi ned ( 59, 60 ) . In our model studies, Gb 3 C16 and C22 showed the best DRM binding for both VT1 and VT2. No binding was seen for VT1 (or gp120) with the intermediate isoforms (C17, C18 and C20), but these Gb 3 DRMs were effectively bound by VT2. This fatty acid modulation of carbohydrate presentation is separate from the lack of GSL carbohydrate ligand binding we have found within the major GSL/cholesterol vesicle fraction (Mahfoud, R., A. Manis, C. Ackerley, and C. Lingwood, unpublished observations) but the principles we observe provide insight in to the basis of membrane regulation of GSL receptors. As for native Gb 3 (Mahfoud, R., A. Manis, C. Ackerley, and C. Lingwood, unpublished observations), gradient DRM vesicles at the 5/30% sucrose interface (the classical 'raft' fraction) were not bound by any ligand for any Gb 3 fatty acid isoform or mixture thereof.
Our evidence indicates that within Gb 3 /cholesterol DRMs, a mere 1-carbon difference within the Gb 3 acyl chain can act as a "switch" to defi ne VT1 (and gp120) binding. The presence of a single isoform within a mixture can determine maximum or minimum binding.
We reconstituted a mixture of Gb 3 fatty acid isoforms in vitro according to mass spectrometry analysis of the human renal Gb 3 fraction. Initially we omitted the only unsaturated species (C24:1). Unsaturation has been generally considered unfavorable for raft formation ( 61 ) . Indeed, C24:1Gb 3 /cholesterol was very poorly/not bound by VT1 and gp120. However, no binding of VT1/gp120 was seen to the mixture of saturated fatty acid Gb 3 isoforms either. The removal of C18Gb 3 , which alone did not bind VT1 in our system, dramatically increased VT1 binding. Despite its minimal presence in the mixture, C18Gb 3 determines the VT1/Gb 3 binding in a dominant negative manner. Removal of C20, which is also unable to support VT1 binding alone, was also suffi cient to induce VT1 binding to the saturated isoform mixture, suggesting C18 and C20Gb 3 have an additive negative effect on VT1 Gb 3 /cholesterol binding. For gp120, removal of both C18 and C20Gb 3 was required to allow binding. Addition of the C24:1 isoform to any mixture of saturated isoforms induced VT1 recognition. Thus C24:1 counteracts the inhibitory effects of C18 and C20Gb 3 . Adding both C24:1 and, for example, C18Gb 3 , neither of which bind VT1 or gp120 alone, induces extensive VT1 and gp120 DRM binding. This is a remarkable property whereby GSL fatty acid isoforms, which show no receptor function, when combined are strongly bound, and it suggests that a balance between rigid and fl uid structures optimizes membrane GSL receptors.
Fatty acid ␣ -hydroxylation shows an effect similar to C24:1. In the single Gb 3 isoform format, hydroxylation inhibited VT1 binding (C22 c.f. C22OH), but if an hydroxylated isoform is added to a mixture of other isoforms for which no DRM binding is seen, DRM binding is signifi cantly increased. ␣ Hydroxylation can mediate Hbonding with GSL headgroups ( 62 ) , but the effect on cholesterol interaction has yet to be reported. GSL fatty acid hydroxylation may decrease fl uidity in a homogeneous system but disturb packing in a mixture to increase by guest, on December 29, 2017 www.jlr.org Downloaded from fl uidity similar to C24:1. Consistent with this, mixing C24:1Gb 3 with C22OH Gb 3 , neither of which shows DRM binding alone, does not induce VT1 binding. This is in stark contrast to mixing C24:1Gb 3 with C18Gb 3 . Thus the "availability" of Gb 3 for VT1 binding within cholesterol complexes is a balance between negative infl uence (C18, C20) and counter-balancers (C24:1, C18OH, C22OH), despite the fact that these counter-balancers do not alone form VT1 bound DRM complexes. We propose that GSL receptor function within liquid-ordered, cholesterolenriched microdomains requires a degree of fl uidity. This fl uidity may allow suffi cient headgroup spacing to accommodate VT1/gp120 recognition. Gb 3 with fatty acids that most closely match the dimensions of conjugated ring system of cholesterol (C17, C18, C20) form a lipid domain too rigid to permit VT1/gp120 binding. These isoforms might sequester the cholesterol to explain their dominant negative effect. It is clear that the Gb 3 fatty acid dependency of VT1 DRM binding is shared by gp120. Both C18 and C20Gb 3 DRMs are not bound. Isoform mixing shows very similar effects for VT1 and gp120. Although C24:1Gb 3 shows little (VT1) or no (gp120) binding, addition in mixes is dominate positive for binding. In the absence of C24:1Gb 3 , C18Gb 3 and C20Gb 3 are dominant negative for binding both ligands. Removal of either will allow VT1 binding, but both must be removed to allow gp120 recognition.
The Langmuir trough monolayer studies verifi ed the C18Gb 3 cut off for VT1 and gp120 but not VT2 binding, found in the DRM constructs. However in this assay, the lack of binding is seen without, rather than with, cholesterol. In addition, gp120 specifi c binding to C20Gb 3 was seen in monolayers but not for Gb 3 DRM vesicles. This difference may refl ect the radius of curvature of the DRM bilayer/ monolayer and that monomeric gp120 requires less fl uidity since lateral pentamer accommodation is unnecessary. Although cholesterol/GSL membranes are more ordered than cholesterol/glycerolipid membranes, pure sphingolipids would form a gel ("solid") phase, which cholesterol converts to the liquid ordered (l o ) phase ( 63 ) . Cholesterol intercalation will thus fl uidize a pure GSL monolayer; C18 and C20Gb 3 monolayers may be too rigid to allow VT1/gp120 binding and insertion. Such rigidity could result from the approximate parity of the chain length of these fatty acids compared with the C18 sphingoid base. In fraction 1 DRM vesicles, the small radius of curvature may suffi ciently reduce GSL/cholesterol bilayer order ( 64 ) to allow ligand binding. The Gb 3 fatty acid independence of VT2 binding in both DRMs and monolayers suggests that Gb 3 fl exibility/fl uidity is less restrictive for VT2 recognition than for VT1 and gp120.
Surface pressures which allow VT1 binding (greater than 30mN/m) are consistent with liquid ordered bilayer binding for VT1, but VT2 and gp120 only bind Gb 3 at lower surface pressures, consistence with "non-raft" membrane Gb 3 binding. This is consistent with the lower Gb 3 DRM binding of VT2 we have reported ( 7 ) and with gp120 cell binding (in progress). However some individual Gb 3 fatty acid homologs show VT2 binding above 30mN/m.
The membrane receptor function of GSL is very complex. Our model studies provide a new investigational tool. The dominant positive effect of C24:1Gb 3 on DRM binding and the remarkable transitions between C16 and C22Gb 3 argue that a degree of fl uidity within a raft is necessary for VT1 (or gp120) binding. Increasing the C24:1 content (but not to homogeneity) promotes ligand binding. In phosphatidylcholine and cholesterol, unsaturation of the Gb 3 fatty acid also increased VT1 binding ( 9 ) . Due to the tendency of unsaturated fatty acid containing GSL to be excluded from lipid rafts ( 28, 30, 31, 65 ) , these results were not anticipated.
The fatty acid dependent regulation of GSL receptor function may provide a physiological basis for the fatty acid selective dihydroceramide synthases ( 60 ) .
